Exact Mass: 453.2304
Exact Mass Matches: 453.2304
Found 500 metabolites which its exact mass value is equals to given mass value 453.2304
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
20-Oxo-leukotriene E4
20-oxo-leukotriene E4 is a metabolite through lipid oxidation of Leukotriene E4 (LTE4).Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 20-oxo-leukotriene E4 is a metabolite through lipid oxidation of Leukotriene E4 (LTE4).Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078)
2-(3-(2-Aminoethyl)-1h-indol-5-yloxy)acetyl-l-tyrosyl-glycinamide
Benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone
2-[[N-Methyl-N-[5-guanidino-2-[(2-amino-3-methylbutyryl)amino]pentanoyl]hydrazino]phosphonyl]-2-hydroxyacetic acid methyl ester
3-O-beta-D-glucopyranosyl-alpha-1-C-(8-hydroxyoctyl)-1-deoxynojirimycin
Leukotriene E4 methyl ester
Ala Ala His Arg
Ala Ala Arg His
Ala His Ala Arg
Ala His Ile Asn
Ala His Lys Val
Ala His Leu Asn
Ala His Asn Ile
Ala His Asn Leu
Ala His Gln Val
Ala His Arg Ala
Ala His Val Lys
Ala His Val Gln
Ala Ile His Asn
Ala Ile Asn His
Ala Lys His Val
Ala Lys Val His
Ala Leu His Asn
Ala Leu Asn His
Ala Asn His Ile
Ala Asn His Leu
Ala Asn Ile His
Ala Asn Leu His
Ala Gln His Val
Ala Gln Val His
Ala Arg Ala His
Ala Arg His Ala
Ala Val His Lys
Ala Val His Gln
Ala Val Lys His
Ala Val Gln His
Cys Phe Gly Lys
Cys Phe Lys Gly
Cys Gly Phe Lys
Cys Gly Lys Phe
Cys Lys Phe Gly
Cys Lys Gly Phe
Phe Cys Gly Lys
Phe Cys Lys Gly
Phe Gly Cys Lys
Phe Gly Lys Cys
Phe Lys Cys Gly
Phe Lys Gly Cys
Gly Cys Phe Lys
Gly Cys Lys Phe
Gly Phe Cys Lys
Gly Phe Lys Cys
Gly His Ile Lys
Gly His Ile Gln
Gly His Lys Ile
Gly His Lys Leu
Gly His Leu Lys
Gly His Leu Gln
Gly His Gln Ile
Gly His Gln Leu
Gly Ile His Lys
Gly Ile His Gln
Gly Ile Lys His
Gly Ile Gln His
Gly Lys Cys Phe
Gly Lys Phe Cys
Gly Lys His Ile
Gly Lys His Leu
Gly Lys Ile His
Gly Lys Leu His
Gly Lys Ser Tyr
Gly Lys Tyr Ser
Gly Leu His Lys
Gly Leu His Gln
Gly Leu Lys His
Gly Leu Gln His
Gly Gln His Ile
Gly Gln His Leu
Gly Gln Ile His
Gly Gln Leu His
Gly Ser Lys Tyr
Gly Ser Tyr Lys
Gly Tyr Lys Ser
Gly Tyr Ser Lys
His Ala Ala Arg
His Ala Ile Asn
His Ala Lys Val
His Ala Leu Asn
His Ala Asn Ile
His Ala Asn Leu
His Ala Gln Val
His Ala Arg Ala
His Ala Val Lys
His Ala Val Gln
His Gly Ile Lys
His Gly Ile Gln
His Gly Lys Ile
His Gly Lys Leu
His Gly Leu Lys
His Gly Leu Gln
His Gly Gln Ile
His Gly Gln Leu
His Ile Ala Asn
His Ile Gly Lys
His Ile Gly Gln
His Ile Lys Gly
His Ile Asn Ala
His Ile Gln Gly
His Lys Ala Val
His Lys Gly Ile
His Lys Gly Leu
His Leu Ala Asn
His Leu Gly Gln
His Leu Asn Ala
His Leu Gln Gly
His Asn Ala Ile
His Asn Ala Leu
His Asn Ile Ala
His Asn Leu Ala
His Asn Pro Ser
His Asn Ser Pro
His Pro Asn Ser
His Pro Ser Asn
His Gln Ala Val
His Gln Gly Ile
His Gln Gly Leu
His Gln Ile Gly
His Gln Leu Gly
His Gln Val Ala
His Arg Ala Ala
His Ser Asn Pro
His Ser Pro Asn
His Val Ala Gln
His Val Gln Ala
Ile Ala His Asn
Ile Ala Asn His
Ile Gly His Gln
Ile Gly Gln His
Ile His Ala Asn
Ile His Gly Gln
Ile His Asn Ala
Ile His Gln Gly
Ile Asn Ala His
Ile Asn His Ala
Ile Pro Pro Gln
Ile Pro Gln Pro
Ile Gln Gly His
Ile Gln His Gly
Ile Gln Pro Pro
Lys Cys Phe Gly
Lys Cys Gly Phe
Lys Phe Cys Gly
Lys Phe Gly Cys
Lys Gly Cys Phe
Lys Gly Phe Cys
Lys Gly Ser Tyr
Lys Gly Tyr Ser
Lys Ser Gly Tyr
Lys Ser Tyr Gly
Lys Tyr Gly Ser
Lys Tyr Ser Gly
Leu Ala His Asn
Leu Ala Asn His
Leu Gly His Gln
Leu Gly Gln His
Leu His Ala Asn
Leu His Gly Gln
Leu His Asn Ala
Leu His Gln Gly
Leu Asn Ala His
Leu Asn His Ala
Leu Pro Pro Gln
Leu Pro Gln Pro
Leu Gln Gly His
Leu Gln His Gly
Leu Gln Pro Pro
Asn Ala His Ile
Asn Ala His Leu
Asn Ala Ile His
Asn Ala Leu His
Asn His Ala Ile
Asn His Ala Leu
Asn His Ile Ala
Asn His Leu Ala
Asn His Pro Ser
Asn His Ser Pro
Asn Ile Ala His
Asn Ile His Ala
Asn Leu Ala His
Asn Leu His Ala
Asn Pro His Ser
Asn Pro Ser His
Asn Ser His Pro
Asn Ser Pro His
Pro His Asn Ser
Pro His Ser Asn
Pro Ile Pro Gln
Pro Ile Gln Pro
Pro Leu Pro Gln
Pro Leu Gln Pro
Pro Asn His Ser
Pro Asn Ser His
Pro Pro Ile Gln
Pro Pro Leu Gln
Pro Pro Gln Ile
Pro Pro Gln Leu
Pro Gln Ile Pro
Pro Gln Leu Pro
Pro Gln Pro Ile
Pro Gln Pro Leu
Pro Ser His Asn
Pro Ser Asn His
Gln Ala His Val
Gln Ala Val His
Gln Gly His Ile
Gln Gly His Leu
Gln Gly Ile His
Gln Gly Leu His
Gln His Ala Val
Gln His Gly Ile
Gln His Gly Leu
Gln His Ile Gly
Gln His Leu Gly
Gln His Val Ala
Gln Ile Gly His
Gln Ile His Gly
Gln Ile Pro Pro
Gln Leu Gly His
Gln Leu His Gly
Gln Leu Pro Pro
Gln Pro Ile Pro
Gln Pro Leu Pro
Gln Pro Pro Ile
Gln Pro Pro Leu
Gln Val Ala His
Gln Val His Ala
Arg Ala Ala His
Arg Ala His Ala
Arg His Ala Ala
Ser Gly Lys Tyr
Ser Gly Tyr Lys
Ser His Asn Pro
Ser His Pro Asn
Ser Lys Gly Tyr
Ser Lys Tyr Gly
Ser Asn His Pro
Ser Asn Pro His
Ser Pro His Asn
Ser Pro Asn His
Ser Tyr Gly Lys
Ser Tyr Lys Gly
Val Ala His Gln
Val Ala Gln His
Val His Ala Gln
Val His Gln Ala
Val Gln Ala His
Val Gln His Ala
Tyr Gly Lys Ser
Tyr Gly Ser Lys
Tyr Lys Gly Ser
Tyr Lys Ser Gly
Tyr Ser Gly Lys
Tyr Ser Lys Gly
Dihexanoyllecithin
PC(6:0/6:0)[S]
Dihexanoylphosphatidylcholine
20-Oxo-leukotriene E4
(S)-2-Fmoc-Amino-Heptanedioic Acid 7-Tert-Butyl Ester
Trioxifene
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist C1892 - Chemopreventive Agent
4-[3-(1-benzhydrylazetidin-3-yl)oxy-2-hydroxypropoxy]-1H-indole-2-carbonitrile
SB590885
SB-590885 is a potent?B-Raf?inhibitor with?Ki?of 0.16 nM, and has 11-fold greater selectivity for B-Raf over c-Raf, without inhibition to other human kinases.
(2S,2S)-2-((2-amino-6-oxo-1H-purin-9(6H)-yl)methoxy)propane-1,3-diyl bis(2-amino-3-methylbutanoate)
Netarsudil
S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics C78283 - Agent Affecting Organs of Special Senses > C29705 - Anti-glaucoma Agent
1H-1-Benzazepine-5-acetamide, 1-(2-chloro-4-(1-pyrrolidinyl)benzoyl)-2,3,4,5-tetrahydro-N-(1-methylethyl)-, (R)-
Urea, N-((1R)-1-(((4S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethyl-1-piperidinyl)carbonyl)-2-methylpropyl)-N-(2-hydroxy-2-methylpropyl)-
Ethoheptazine citrate
C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist
2,5-Bis(5-carboxy-3-ethyl-4-methylpyrrol-2-ylmethyl)-3,4-diethylpyrrole
N-{1-[(1-carbamoylcyclopropyl)methyl]piperidin-4-yl}-N-cyclopropyl-4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide
(20s)-19,20,22,23-Tetrahydro-19-oxo-5h,21h-18,20-ethano-12,14-etheno-6,10-methenobenz[d]imidazo[4,3-l][1,6,9,13]oxatriazacyclonoadecosine-9-carbonitrile
[(2R)-1-[(2S)-2-[[(2S,3S)-1-Chloro-6-(diaminomethylideneamino)-2-hydroxyhexan-3-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]azanium
(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-5-hydroxy-20-oxoicosa-7,9,11,14-tetraenoic acid
2-(3-(2-Aminoethyl)-1h-indol-5-yloxy)acetyl-l-tyrosyl-glycinamide
Benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone
3-Demethylstaurosporinium(1+)
Conjugate acid of 3-demethylstaurosporine.
(1S,2R,5S,7S,12S,15S)-7-(2-hydroxypropan-2-yl)-1,2-dimethyl-6,10-dioxa-24-azaheptacyclo[13.10.0.02,12.05,11.09,11.017,25.018,23]pentacosa-17(25),18,20,22-tetraene-8,12-diol
3,5-Dimethyl-1-phenyl-4-pyrazolecarboxylic acid [2-[4-amino-1-methyl-3-(2-methylpropyl)-2,6-dioxo-5-pyrimidinyl]-2-oxoethyl] ester
(3R,3aS,7R,7aS)-3-[3-(4-acetylphenyl)-4-fluorophenyl]-7-methyl-2-(phenylmethyl)-3a,6,7,7a-tetrahydro-3H-isoindol-1-one
(3R,3aR,7aR)-3-[4-(4-acetylphenyl)-2-fluorophenyl]-7a-methyl-2-(phenylmethyl)-3,3a,6,7-tetrahydroisoindol-1-one
(5aS,7S,8aR,9aS)-7,7,8,8-tetramethyl-5a-nitrospiro[1,2,3,5,6,8a,9,9a-octahydrocyclopenta[f]indolizine-7,3-1,8-dihydropyrano[2,3-g]indole]-2,9-dione
(E)-3,7,11,15-tetramethylhexadec-2-en-1-yl diphosphate(3-)
N-[2-methyl-4-oxo-3-(phenylmethyl)-7-(1-piperidinyl)-6-quinazolinyl]-3-pyridinecarboxamide
4-tert-butyl-N-[2,5-dimethoxy-4-[[1-oxo-2-(1-piperidinyl)ethyl]amino]phenyl]benzamide
3-butan-2-yl-1-[(6,7-dimethoxy-2-oxo-1H-quinolin-3-yl)methyl]-1-(2-phenylethyl)thiourea
1-(4-amino-1,2,5-oxadiazol-3-yl)-5-(azepan-1-ylmethyl)-N-[(E)-(2-ethoxyphenyl)methylidene]-1H-1,2,3-triazole-4-carbohydrazide
2-[[[4-[[5-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]pentylamino]-oxomethyl]-1H-imidazol-5-yl]-oxomethyl]amino]acetic acid tert-butyl ester
1-(4-Amino-1,2,5-oxadiazol-3-YL)-N-[(E)-(2-ethoxyphenyl)methylidene]-5-[(4-methylpiperidin-1-YL)methyl]-1H-1,2,3-triazole-4-carbohydrazide
3-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(4-morpholinyl)ethyl]-1-oxo-3,4-dihydroisoquinoline-4-carboxamide
N-[(2-methoxyphenyl)methyl]-4-[[[2-(4-methyl-1-piperidinyl)-3,4-dioxo-1-cyclobutenyl]amino]methyl]-1-cyclohexanecarboxamide
1-(4-Amino-1,2,5-oxadiazol-3-YL)-N-[(E)-(4-ethoxyphenyl)methylidene]-5-[(4-methylpiperidin-1-YL)methyl]-1H-1,2,3-triazole-4-carbohydrazide
N-[(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
N-[[(2R,3R)-8-[2-(4-fluorophenyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
1-[(1S)-2-[(2-fluorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
1-[(1R)-2-[(2-fluorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
N-[(2S,3R)-4-[(4-fluorophenyl)carbamoyl-[(2S)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-N-methyloxane-4-carboxamide
N-[(2R,3R)-4-[(4-fluorophenyl)carbamoyl-[(2R)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-N-methyloxane-4-carboxamide
methyl (1S,9R,10R,11R)-5-[3-(dimethylcarbamoyl)phenyl]-10-(hydroxymethyl)-6-oxo-12-propyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylate
N-[(2S,3R)-4-[(4-fluorophenyl)carbamoyl-[(2R)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-N-methyloxane-4-carboxamide
N-[(2R,3R)-4-[[(4-fluoroanilino)-oxomethyl]-[(2S)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-N-methyl-4-oxanecarboxamide
N-[(2R,3S)-4-[(4-fluorophenyl)carbamoyl-[(2R)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-N-methyloxane-4-carboxamide
methyl (1R,9S,10S,11S)-5-[3-(dimethylcarbamoyl)phenyl]-10-(hydroxymethyl)-6-oxo-12-propyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylate
N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
N-[(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide
N-[[(2R,3S)-8-[2-(4-fluorophenyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
N-[[(2S,3R)-8-[2-(4-fluorophenyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
N-[[(2R,3R)-8-[2-(4-fluorophenyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
1-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-propylurea
1-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-propylurea
1-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-propylurea
N-[(5S,6S,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(5S,6R,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(5S,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(5R,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(5R,6R,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4S,7S,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4S,7S,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(2S,3R,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2R,3R,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2S,3S,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2R,3S)-4-[[(4-fluoroanilino)-oxomethyl]-[(2S)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-N-methyl-4-oxanecarboxamide
(3aR,4R,9bS)-8-(1-cyclohexenyl)-N-(2,5-difluorophenyl)-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinoline-1-carboxamide
[(3aR,4S,9bS)-4-(hydroxymethyl)-8-[2-(4-methoxyphenyl)ethynyl]-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-pyridin-4-ylmethanone
(6R,7R,8S)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8R)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8R)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8R)-8-(hydroxymethyl)-7-[4-[(E)-2-phenylethenyl]phenyl]-4-(2-pyridin-3-ylacetyl)-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7S,8S)-8-(hydroxymethyl)-7-[4-[(E)-2-phenylethenyl]phenyl]-4-(2-pyridin-3-ylacetyl)-1,4-diazabicyclo[4.2.0]octan-2-one
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
N-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide
N-[[(2S,3R)-8-[2-(4-fluorophenyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
N-[[(2R,3S)-8-[2-(4-fluorophenyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
N-[[(2S,3S)-8-[2-(4-fluorophenyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
N-[[(2S,3S)-8-[2-(4-fluorophenyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
1-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-propylurea
1-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-propylurea
1-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-propylurea
1-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-propylurea
1-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-propylurea
N-[(5S,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(5R,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4R,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4S,7R,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4R,7R,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4R,7S,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4R,7S,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4S,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(2R,3S,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2S,3R,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2R,3S,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2S,3S,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2R,3R,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2S,3S)-4-[[(4-fluoroanilino)-oxomethyl]-[(2R)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-N-methyl-4-oxanecarboxamide
N-[(2S,3S)-4-[[(4-fluoroanilino)-oxomethyl]-[(2S)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-N-methyl-4-oxanecarboxamide
(6S,7S,8S)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7S,8S)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8R)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8R)-8-(hydroxymethyl)-7-[4-[(E)-2-phenylethenyl]phenyl]-4-(2-pyridin-3-ylacetyl)-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8S)-8-(hydroxymethyl)-7-[4-[(E)-2-phenylethenyl]phenyl]-4-(2-pyridin-3-ylacetyl)-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8R)-8-(hydroxymethyl)-7-[4-[(E)-2-phenylethenyl]phenyl]-4-(2-pyridin-3-ylacetyl)-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8S)-8-(hydroxymethyl)-7-[4-[(E)-2-phenylethenyl]phenyl]-4-(2-pyridin-3-ylacetyl)-1,4-diazabicyclo[4.2.0]octan-2-one
[(1S)-2-(cyclopropylmethyl)-1-[(2,5-difluorophenyl)methyl]-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
(1R,9S,10S,11S)-10-(hydroxymethyl)-N-[2-(1-methylimidazol-4-yl)ethyl]-6-oxo-12-propanoyl-5-[(Z)-prop-1-enyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1S,9R,10R,11R)-10-(hydroxymethyl)-N-[2-(1-methylimidazol-4-yl)ethyl]-6-oxo-12-propanoyl-5-[(Z)-prop-1-enyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
5-aminopentyl 3-O-(2-O-acetyl-6-deoxy-alpha-L-talopyranosyl)-beta-D-glucopyranoside
2-amino-3-[hydroxy-[2-hydroxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] undecanoate
(3-Butanoyloxy-2-octanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] dodecanoate
(3-Acetyloxy-2-decanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] octanoate
(2-Heptanoyloxy-3-pentanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
[1-Acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] tridecanoate
(2-Nonanoyloxy-3-propanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] decanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] nonanoate
1,2-Dihexanoyl-sn-glycero-3-PC
A phosphatidylcholine 12:0 in which both acyl groups are specified as hexanoyl.
20-oxoleukotriene E4
A leukotriene that is leukotriene E4 in which the terminal methyl grop has been oxidised to the corresponding aldehyde
phosphatidylcholine 12:0
A 1,2-diacyl-sn-glycero-3-phosphocholine in which the two acyl groups contain a total of 12 carbons and no double bonds.
Phe-Pro-Ala-pNA
Phe-Pro-Ala-pNA is a chromogenic substrate of tripeptidyl peptidase. Phe-Pro-Ala-pNA can be used to test tripeptidyl peptidase activity[1].
Temuterkib
Temuterkib (LY3214996) is a highly selective inhibitor of ERK1 and ERK2, with IC50 of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.